ODYSSEY Outcomes trial.
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.
Mildura Cardiology took part in this trial of a new cholesterol-lowering agent in people with coronary artery disease who had failed to reach target levels with maximally tolerated doses of currently available medications.
The trial ran from October 2012 until January 2018. It was an international, multicentre study with a total of 18,600 patients randomised. Australia enrolled 216 patients from approximately 20 sites.
Mildura Cardiology enrolled 16 patients, and Leanne Morgan accepted a certificate of appreciation at a presentation in Brisbane, for our contribution to this important study as a high recruiter.
Our thanks go to our 16 patients who gave up their time to help with the study.